The Association of Rehabilitation Medicine in Manitoba Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2013
NCT01896037
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

eicosapentanoic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Quadriplegia (Phase 4)

Spinal Cord Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1